Pneumonia in elderly patients with chronic obstructive pulmonary disease
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
This article reviews the association between pneumonia and chronic obstructive pulmonary disease (COPD) and the possible role of inhaled corticosteroids in increasing the risk of pneumonia in patients with COPD. An increased risk of pneumonia with inhaled corticosteroids was first reported from the Toward Revolution in COPD Health (TORCH) study, a large randomized clinical trial comparing fluticasone, salmeterol, or a combination of the two medications with placebo. We carried out a large observational study using a health care administrative database of information on hospitalizations and medication use among patients older than 65 years of age in Quebec. We found an excess of pneumonia requiring hospitalization and an excess of pneumonia hospitalizations leading to death in relation to current use of inhaled corticosteroids, especially at high doses. Here, we explore the potential mechanisms of this association and try to weigh the benefits and risks of therapy with inhaled corticosteroids in patients with COPD.
- Mannino DM, Homa DM, Akinbami LJ, et al.: Chronic obstructive pulmonary disease surveillance—United States, 1971–2000. MMWR Surveill Summ 2002, 51:1–16.
- Chapman KR, Mannino DM, Soriano JB, et al.: Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J 2006, 27:188–207. CrossRef
- Lopez AD, Murray CC: The global burden of disease, 1990–2020. Nat Med 1998, 4:1241–1243. CrossRef
- Buist AS, McBurnie MA, Vollmer WM, et al.: International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007, 370:741–750. CrossRef
- O’Donnell DE, Aaron S, Bourbeau J, et al.: Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease—2007 update. Can Respir J 2007, 14(Suppl B):5B–32B.
- Fry AM, Shay DK, Holman RC, et al.: Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988–2002. JAMA 2005, 294:2712–2719. CrossRef
- Lange P, Vestbo J, Nyboe J: Risk factors for death and hospitalization from pneumonia. A prospective study of a general population. Eur Respir J 1995, 8:1694–1698. CrossRef
- Almirall J, Bolibar I, Balanzo X, Gonzalez CA: Risk factors for community-acquired pneumonia in adults: a population-based case-control study. Eur Respir J 1999, 13:349–355. CrossRef
- Restrepo MI, Mortensen EM, Pugh JA, Anzueto A: COPD is associated with increased mortality in patients with community-acquired pneumonia. Eur Respir J 2006, 28:346–351. CrossRef
- Rello J, Rodriguez A, Torres A, et al.: Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia. Eur Respir J 2006, 27:1210–1216. CrossRef
- Torres A, Menendez R: Mortality in COPD patients with community-acquired pneumonia: who is the third partner? Eur Respir J 2006, 28:262–263. CrossRef
- Anthonisen NR, Connett JE, Enright PL, Manfreda J: Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002, 166:333–339. CrossRef
- Monso E, Ruiz J, Rosell A, et al.: Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995, 152(4 Pt 1):1316–1320.
- Wedzicha JA, Seemungal TA: COPD exacerbations: defining their cause and prevention. Lancet 2007, 370:786–796. CrossRef
- Calverley PM, Anderson JA, Celli B, et al.: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356:775–789. CrossRef
- Kardos P, Wencker M, Glaab T, Vogelmeier C: Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 175:144–149. CrossRef
- Suissa S: Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006, 173:842–846. CrossRef
- Wedzicha JA, Calverley PM, Seemungal TA, et al.: The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008, 177:19–26. CrossRef
- Ernst P, Gonzalez AV, Brassard P, Suissa S: Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007, 176:162–166. CrossRef
- Wolfe F, Caplan L, Michaud K: Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia. Arthritis Rheum 2006, 54:628–634. CrossRef
- Lipworth BJ: Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Arch Int Med 1999, 159:941–955. CrossRef
- Christ-Crain M, Stolz D, Jutla S, et al.: Free and total cortisol levels as predictors of severity and outcome in community-acquired pneumonia. Am J Respir Crit Care Med 2007, 176:913–920. CrossRef
- Garcia-Vidal C, Calbo E, Pascual V, et al.: Effects of systemic steroids in patients with severe community-acquired pneumonia. Eur Respir J 2007, 30:951–956. CrossRef
- Confalonieri M, Urbino R, Potena A, et al.: Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005, 171:242–248. CrossRef
- Hogg JC, Chu FS, Tan WC, et al.: Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. Am J Respir Crit Care Med 2007, 176:454–459. CrossRef
- Barnes PJ: Current Issues for establishing inhaled corticosteroids as the antiinflammatory agents of choice in asthma. J Allergy Clin Immunol 1998, 101(4 Pt 2):S427–S433. CrossRef
- Qaseem A, Snow V, Shekelle P, et al.: Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2007, 147:633–638.
- Van Andel AE, Reisner C, Menjoge SS, Witek TJ: Analysis of inhaled corticosteroid and oral theophylline use among patients with stable COPD from 1987 to 1995. Chest 1999, 115:703–707. CrossRef
- Burge PS, Calverley PM, Jones PW, et al.: Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br Med J 2000, 320:1297–1303. CrossRef
- Lung Health Study Research Group: Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000, 343:1902–1909. CrossRef
- Alsaeedi A, Sin DD, McAlister FA: The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: A systematic review of randomized placebo-controlled trials. Am J Med 2002, 113:59–65. CrossRef
- Aaron SD, Vandemheen KL, Fergusson D, et al.: Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007, 146:545–555.
- La Vecchia C, Fabbri LM: Prevention of death in COPD. N Engl J Med 2007, 356:2211–2212. CrossRef
- Garbe E, Suissa S, LeLorier J: Association of inhaled corticosteroid use with cataract extraction in elderly patients. JAMA 1998, 280:539–543. CrossRef
- Suissa S, Baltzan M, Kremer R, Ernst P: Inhaled and nasal corticosteroid use and the risk of fracture. Am J Respir Crit Care Med 2004, 169:83–88. CrossRef
- Pneumonia in elderly patients with chronic obstructive pulmonary disease
Current Infectious Disease Reports
Volume 10, Issue 3 , pp 223-228
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links